Needham & Company LLC Cuts Earnings Estimates for Teleflex

Teleflex Incorporated (NYSE:TFX) – Equities research analysts at Needham & Company LLC dropped their FY2025 earnings per share estimates for shares of Teleflex in a research report issued on Tuesday, January 27th. Needham & Company LLC analyst M. Matson now anticipates that the medical technology company will post earnings per share of $13.96 for the year, down from their prior forecast of $14.11. Needham & Company LLC has a “Buy” rating and a $138.00 price objective on the stock. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, November 6th. The medical technology company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.38 by $0.29. Teleflex had a positive return on equity of 15.64% and a negative net margin of 10.28%.The company had revenue of $892.90 million during the quarter, compared to analysts’ expectations of $892.79 million. During the same period in the prior year, the business earned $3.49 earnings per share. Teleflex’s revenue for the quarter was up 19.4% compared to the same quarter last year. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS.

A number of other research firms also recently weighed in on TFX. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Truist Financial raised their price objective on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research report on Thursday, December 18th. Wall Street Zen cut Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Wells Fargo & Company reduced their target price on Teleflex from $139.00 to $116.00 and set an “equal weight” rating for the company in a research report on Thursday. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $135.00 price target on shares of Teleflex in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Teleflex has an average rating of “Hold” and a consensus target price of $139.00.

Teleflex Stock Performance

NYSE TFX opened at $105.45 on Friday. The company’s fifty day moving average is $116.22 and its two-hundred day moving average is $119.63. Teleflex has a 52-week low of $100.18 and a 52-week high of $184.58. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.57 and a quick ratio of 1.53. The firm has a market capitalization of $4.66 billion, a price-to-earnings ratio of -14.35, a P/E/G ratio of 1.38 and a beta of 0.93.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. AQR Capital Management LLC raised its stake in shares of Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after buying an additional 1,956,811 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Teleflex by 0.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,245,614 shares of the medical technology company’s stock valued at $152,408,000 after acquiring an additional 3,812 shares during the last quarter. Cooke & Bieler LP lifted its stake in shares of Teleflex by 1.2% in the 3rd quarter. Cooke & Bieler LP now owns 1,220,637 shares of the medical technology company’s stock valued at $149,357,000 after purchasing an additional 14,673 shares during the period. Abrams Bison Investments LLC acquired a new position in shares of Teleflex in the 3rd quarter valued at $112,317,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Teleflex by 123.9% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 660,800 shares of the medical technology company’s stock worth $80,855,000 after purchasing an additional 365,663 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 15th. Investors of record on Friday, November 14th were issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend was Friday, November 14th. Teleflex’s dividend payout ratio (DPR) is currently -18.50%.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.